2 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Spirig Pharma Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis Sertaconazole 2% cream, Placebo - Skin Alterations Associated With Atopic Dermatitis | Phase 2 | Completed | Spirig Pharma Ltd. | 70 | 2013-02-01 | 2015-05-20 |
| Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma 0.06% Resiquimod Gel - A, 0.06% Resiquimod Gel - B, 0.06% Resiquimod Gel - C - Nodular Basal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Spirig Pharma Ltd. | 4 | 2013-02-01 | 2016-06-22 |
| Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions Resiquimod 0.03%, Resiquimod 0.01%, placebo - Actinic Keratosis | Phase 2 | Completed | Spirig Pharma Ltd. | 218 | 2012-05-01 | 2015-12-15 |
Dermatitis, Atopic (1) · Keratosis, Actinic (1)
sertaconazole (1)
Germany (3) · Switzerland (2)
Lars E French, MD (1) · R Dummer, PrMD (1)